US Capitol Capsule: Sequester threatens FDASIA success, Woodcock says
This article was originally published in Scrip
Executive Summary
A hearing on 15 November of the House Energy and Commerce Health Subcommittee was not only an opportunity for the heads of the FDA's drug and device centers to brag on the progress the agency has made in implementing the Food and Drug Administration Safety and Innovation Act (FDASIA), but it also gave lawmakers a forum at which to crow about one of the few accomplishments they've made in the past year in the current rancorous Washington environment.